Generalizability of the Results of Efficacy Trials in First-Episode Schizophrenia: Comparisons Between Subgroups of Participants of the European First Episode Schizophrenia Trial (EUFEST)
J Clin Psychiatry 2010;71(1):58-65
© Copyright 2016 Physicians Postgraduate Press, Inc.
Purchase This PDF for $40.00
If you are not a paid subscriber, you may purchase the PDF.
(You'll need the free Adobe Acrobat Reader.)
Receive immediate full-text access to JCP. You can subscribe to JCP online-only ($86) or print + online ($156 individual).
With your subscription, receive a free PDF collection of the NCDEU Festschrift articles. Hurry! This offer ends December 31, 2011.
If you are a paid subscriber to JCP and do not yet have a username and password, activate your subscription now.
As a paid subscriber who has activated your subscription, you have access to the HTML and PDF versions of this item.
Click here to login.
Did you forget your password?
Still can't log in? Contact the Circulation Department at 1-800-489-1001 x4 or send email
Objective: Most randomized drug trials in schizophrenia exclude patients with comorbidities such as suicidality or substance use, which may limit the generalizability of the results. We aimed
to evaluate the generalizability of the results of these trials in participants of a randomized
clinical trial with broad inclusion criteria.
Method: In 50 sites in 14 countries, 498 patients with first-episode psychosis (DSM-IV schizophrenia, schizoaffective disorder, or schizophreniform disorder) were recruited between December 2002 and January 2006 in an open, randomized clinical drug trial with 12 months of follow-up. Baseline characteristics and follow-up data were compared between patients with versus patients without
baseline suicidality and/or substance use.
Results: Of the 489 participants with data on baseline suicidality and substance use, 153 (31%) patients were suicidal and/or using substances. Groups differed on only a few of the many baseline characteristics tested: comorbid patients were younger (25.1 vs 26.5 years of age; P < .01), less often female (25% vs 47%; P < .001) or married (4% vs 17%; P < .001), had fewer years of education (11.8 vs 12.8; P < .001), and experienced lower levels of overall psychosocial functioning (Global Assessment of Functioning; 38.4 vs 40.8; P ≤ .05) and higher levels of depression (Calgary Depression Scale for Schizophrenia; 6.1 vs 4.6; P < .001). At follow-up, comorbid patients showed shorter time to (re)hospitalization and reported higher levels of depression than patients without comorbidity (hazard ratio = 2.02, P = .004; χ27 = 17.25, P = .016, respectively), without differences on other outcome measures.
Conclusions: Although it appears that the
generalizability of antipsychotic treatment trials
in first-episode patients is not seriously affected by the exclusion of patients with suicidal symptoms and/or substance use, researchers should be cautious about the exclusion of such patients.
Trial Registration: controlled-trials.com
Submitted: July 1, 2008; accepted Dec 1, 2008.
Online ahead of print: October 20, 2009
Corresponding author: Han Boter, PhD, Department of Epidemiology (room FA 40), University Medical Centre Groningen, PO Box 30001,
NL-9700 RB Groningen, The Netherlands (H.Boter@epi.umcg.nl).